key: cord-0795657-trs29vmr
authors: Mudrick, Haley E.; McGlinch, Erin B.; Parrett, Brian J.; Hemsath, Jack R.; Barry, Mary E.; Rubin, Jeffrey D.; Uzendu, Chisom; Hansen, Michael J.; Erskine, Courtney L.; VanKeulen, Virginia P.; Drelich, Aleksandra; Tseng, Chien-Te Kent; Massey, Shane; Fida, Madiha; Suh, Gina A.; Peikert, Tobias; Block, Matthew S.; Olivier, Gloria R.; Barry, Michael A.
title: Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines
date: 2021-04-20
journal: bioRxiv
DOI: 10.1101/2021.04.20.440651
sha: cb263036336e62416df7a27818048466cd3e0af0
doc_id: 795657
cord_uid: trs29vmr

SARS-CoV-2 enters the body at mucosal surfaces, such as the nose and lungs. These events involve a small number of virions at these mucosal barriers and are therefore a strategic point to stop a COVID-19 infection before it starts. Despite this, most vaccines against COVID-19 are being injected into the muscle where they will not generate the highest levels of mucosal protection. The vaccines that are approved for use in humans are all replication-defective (RD) mRNA, DNA, or adenovirus (Ad) vaccines that do not amplify antigen transgenes. We developed single cycle adenovirus (SC-Ad) vectors that replicate antigen genes up to 10,000-fold in human cells, but that are disabled from producing infectious Ad particles. We show here that SC-Ad expressing the full-length SARS-CoV-2 spike protein produces 100-fold more spike protein than a matched RD-Ad-Spike vector. When Ad-permissive hamsters were immunized with these vaccines by intranasal (IN) or intramuscular (IM) routes, SC-Ad produced significantly stronger antibody responses as compared to RD-Ad against the spike protein that rose over 14 weeks after one immunization. Single IN or IM immunizations generated significant antibody responses in serum and in bronchoalveolar lavages (BALs). IN priming, but not IM priming, generated HLA-restricted CD8 T cell responses in BALs. SC-Ad-Spike generated antibodies that retain binding to spike receptor binding domains (RBDs) with mutations from new viral variants. These data suggest empowering the genomes of gene-based vaccines with the ability to amplify antigen genes can increase potency. This may be particularly advantageous when applying mucosal vaccines to combat mucosal pathogens like SARS-CoV-2. One Sentence Summary Arming adenovirus vaccines with the ability to replicate vaccine antigen genes may increase potency for systemic, or more importantly, mucosal immunization against mucosal pathogens.

In December 2019, a cluster of pneumonia cases were identified in Wuhan, China, which 67

were later found to be caused by a novel coronavirus: severe acute respiratory syndrome Recomb TM Protein A/G Peroxidase Conjugated (Invitrogen). Plates were left to incubate 209 with the primary antibody for 2 hours at room temperature. Plates were washed with 200 210 µl 1X PBS 4 times. 50 µl 1-Step TM Ultra TMB-ELISA was added to each well and left at 211 room temperature for 30 minutes, then 50 µl 2M sulfuric acid was added to each well. 212

Plates were read at 450nm in a Synergy H1 microplate reader (BioTek). All statistical 213 analyses were done by one-way ANOVA. 214 ELISPOT Assay for Detecting Antigen-specific IFN-γ producing Cells. Freshly-217 isolated splenocytes were stimulated with spike S1 or S2 subunit protein (1 µg/mL) to 218 determine the numbers of IFN-γ-producing cells by the Enzyme Linked Immuno Spot 219 (ELISPOT) assay using the methodology reported previously (30). Briefly, splenocytes 220 were plated at 2.5 × 10 5 cells per well in triplicate in 96-well plates. Cells were incubated 221 at 37 °C with medium alone, human papilloma virus E7 peptide (negative control), SARS-222

CoV-2 spike protein S1 subunit (1 µg/ml), SARS-CoV-2 spike protein S2 subunit (1 223 µg/ml), tetanus toxoid (TT, negative control, 100ng/ml)), or concanavalin A (Con A), This cDNA uses all native spike sequences and secretory leader and does not bear 12 modifications such as proline mutations to alter spike structure (4, 5, 31). This cDNA was 258 inserted into a cytomegalovirus (CMV) expression cassette and was used to generate 259 human adenovirus serotype 6 (HAdV-C6, Ad6) vectors RD-Ad6-spike and SC-Ad6-spike, 260 respectively (Fig. 1A) . These vectors were tested for spike protein expression by infection 261 of human A549 lung cells at varied multiplicities of infection (MOI) (Fig. 1B) . Western blot 262 on cells harvested 24 hours after infection demonstrated that both vectors produced spike 263 protein; however, RD-Ad-Spike only generated detectable protein with 10 4 virus particles 264

(vp) per cell, but not with 100 vp/cell. In contrast, SC-Ad-Spike produced protein with 100 265 or more vp/cell with higher expression than RD-Ad at each dose. 266

Adenovirus-permissive Syrian Hamsters. Human Ad6 replicates its genome up to 268 100,000-fold in human cells (32, 33). SC-Ad replicates DNA identically to RC-Ad (33). collected at varied times thereafter (Fig. 2) . Under these conditions, SC-Ad-Spike 281 generated significantly higher spike antibody levels than RD-Ad-GL or SC-Ad-GL 282 expressing GFP-Luciferase or when compared to RD-Ad-Spike at a fixed dilution 283

(1/1,000) of sera. SC-Ad-Spike delivered by the intramuscular route generated higher IgG 284 at all time points through 6 months after single immunization (p < 0.0001 by ANOVA) 285 ( Figs. 2 and 3C and D) . SC-Ad-Spike by the intranasal route generated significantly 286 higher IgG in sera at 6 weeks and 14 weeks, but not at 2 weeks and 6 months after single 287 immunization (p < 0.0001 and p < 0.001 at 6 and 14 weeks). Serial dilution of these sera 288 samples revealed reciprocal endpoint spike binding titers of 100 for RD-Ad-Spike by both 289 routes (Fig. 3A) . In contrast, SC-Ad-Spike by IN route had reciprocal binding titers of 290 1,000 (p < 0.05). SC-Ad-Spike by the IM route had reciprocal titers of 1,000 or greater (p 291 < 0.0001). This experiment was repeated in female Syrian hamsters with similar results 292 (Supplemental Figs. 2 and 3) . 293

Varied dilutions of 6-week sera were assayed for SARS-CoV-2 neutralization antibodies 294 with the cPass TM Neutralization Antibody Detection kit that assays antibodies that block 295 binding of spike receptor binding domain (RBD) to ACE2. Under these conditions, RD-Ad 296 vaccinated hamsters failed to generate significant spike RBD inhibition at any dilution. In 297 contrast, animals immunized with SC-Ad-Spike by the IN and IM route had significantly 298 higher inhibition at all dilutions than RD-Ads within 6 weeks of single immunization (Fig.  299   3B) . considering that they can impact the ability of neutralizing antibodies to block binding of 310 the spike protein to ACE2. 311

Given concerns about these variants, week 14 sera from hamsters immunized IM with 312 the negative control vaccine SC-Ad-GL and SC-Ad-Spike ( Fig. 2 and 3) were compared 313 for their ability to bind spike RBD (amino acids 319 to 541) and S1 variants (amino acids 314 16 to 685)( Fig. 4 and Supplemental Fig. 3) . The RBD from the original SARS virus was 315 also included as a reference. ELISAs performed at 1/1,000 dilutions demonstrated 316 significant binding by samples from SC-Ad-Spike immunized animals to all the variant 317 RBDs and S1 proteins when compared to SC-Ad-GL samples (p < 0.0001 by one-way 318 ANOVA). SC-Ad-Spike bound the RBD from the original SARS-1 virus, but this did not 319 reach significance at 1/1,000. When the samples were tested at 1/10,000 dilutions binding 320 remained significant with p values remaining less than 0.0001 for all samples except the 321 RBD with combined K417N, E484K, N501Y, which fell to a p value of less than 0.01. 322 ELISA binding to the single E484K RBD was higher at this dilution than to other RBDs, 323 suggesting some difference in structure or an artifact. When further 1/20,000 dilutions 324 were tested, binding to all variants was still significantly different between SC-Ad-Spike 325 and SC-Ad-GL samples (p < 0.05 to 0.0001), except for K417N, E484K, N501Y RBD, 326 which was no longer significantly different. While binding to the K417N, E484K, N501Y 327 RBD was lost, binding to the larger S1 protein with K417N, E484K, N501Y, and D614G 328 mutations remained significant (p < 0.01). This was not unexpected, since the larger spike 329 S1 protein has many more epitopes for polyclonal antibody binding. 330 Fig. 5) . 339

Lungs. Five animals from selected groups in Fig. 5 were sacrificed 8 weeks after single 341 immunization and bronchoalveolar lavages (BALs) were performed to collect mucosal 342 antibodies and immune cells from the lungs. The 3 mL BAL washes were diluted 1/500 343 and were used to detect anti-spike IgG and IgA antibodies by ELISA. By 8 weeks after 344 single immunization, the mice had significant levels of IgG antibodies in their BALs (p < 16 0. 01 and 0.001, Fig. 6A) . Notably, significant anti-spike IgA antibodies were only 346 observed in IN-immunized mice (p < 0.01). When BAL samples were tested for RBD 347 neutralizing activity, both the IN and IM-immunized mice had significant activities (p < 348 0. 01 and 0.05, respectively, Fig. 6B) . 349

BAL samples were also examined for the presence of T cells in the lung. The small 351 number of cells obtained and an absence of known spike T cell epitopes for BALB/c mice 352 precluded testing for spike-specific responses; however, when flow cytometry was 353 performed, IFN-g and IL-4-expressing CD4 and CD8 T cells were detected in BAL 354 samples (Fig. 7) . These analyses revealed no significant increases in CD4 or CD8 T cells 355 in BAL samples after IM immunization. In contrast, there were significant increases in 356 CD8 + IFN-g + , CD4 + IFN-g + , and CD4 + IL-4 + T cells in the BALs of animals immunized 357 intranasally with either SC-Ad-Zika E or SC-Ad-Spike. 358 Fig. 7 were assayed for IFN-g, IL-17, and IL-4-expression by ELISPOT 360 after stimulation with spike S1 whole protein subunit (Supplemental Fig. 4) . These data 361 demonstrated higher splenocyte IFN-g, IL-17, and IL-4 responses in the BALB/c mice after 362 IN immunization than after IM immunization. 363

The purpose of this study was to compare RD-and SC-Ad vaccines expressing the 365 SARS-CoV-2 spike protein and to evaluate whether mucosal immunization may have 366 utility when considering vaccines against a mucosal pathogen like SARS-CoV-2. These 367 data suggest that vaccines that retain the ability to replicate their DNA can drive more 368 potent and long-lasting immune responses than non-replicating vaccines. These data 369 also suggest that there may be advantages to delivering vaccines at mucosal sites by 370 single immunization or as a prime followed by later boost. were higher in animals immunized by the intramuscular route than the intranasal route. 376

In all the animal models, antibody titers were higher in ELISA assays than in varied 377 neutralization assays, as expected. This may reflect, in part, the use of the wild-type spike 378 protein sequence rather than modified spikes locked in the "up" position (4). Use of such 379 a modified spike would likely increase neutralization by SC-Ad. 380 SC-Ad-Spike generated antibodies from these hamsters were able to cross-react in 381 ELISA assays against several single point mutant RBD variants, including those observed 382 in the U.K. B.1.1.7 strain and the South African B.1.351 strain. These antibodies were 383 also able to bind K417N, E484K, N501Y RBD at 1/1,000 and 1/10,000 dilutions in ELISA, 384 but were insignificant at 1/20,000 dilutions. This was not surprising given that the 385 presence of three separate mutations have been shown to affect the ability of Pfizer, 386

Moderna, and other vaccines to recognize these new variants. 387

18 The single-cycle replication "engine" can be applied to any adenovirus serotype. This 388 increased potency could be utilized in two ways. In one, SC-Ad is delivered at the same 389 virus particle doses as current RD-Ad COVID-19 vaccines to garner stronger immune 390 responses. In the second, SC-Ad is used at a lower dose, perhaps 10 to 100-fold lower, 391 to deliver equal potency to RD-Ad vaccines, but allowing 10 to 100 times more vaccine 392 doses from the same size of a GMP vaccine production run. This could be pivotal for 393 expanding access to vaccines for this pandemic or the next to vaccinate people in rich 394 and poorer countries. 395

Species C human Ad6 was used to test proof of concept since it is equal to or is more 396 robust than species C Ad5 as a vaccine or as an oncolytic (32, 38-42). Species C Ad5 397 and Ad6 also appear to be more robust as gene-based vaccines than lower seroprevalent 398 viruses like species D Ad26 and species E ChAdOx1 (38, 39, 43, 44) . 399

Another interesting aspect of this work was examining if there is utility in applying these 400 gene-based vaccines at mucosal surfaces. Hamsters have few immune reagents, so this 401 was examined in more detail in mouse models. In mice, we show that intranasal 402 immunization generated equal IgG antibodies in the lungs of mice, but higher IgA and 403 there may be benefits in priming the immune system at mucosal sites when immunizing 417 against pathogens that also enter at these sites. 418

Mucosal immunization may also have utility to impact vaccine safety. There are concerns 419 with observations of thrombotic thrombocytopenia in a small number of people who have 420 received the Ad26 and ChAdOx1 COVID-19 (45, 46) . These vaccines were delivered by 421 the intramuscular route. Adenoviruses do not naturally infect the muscle. Ads naturally 422 infect humans at some mucosal site (reviewed in (47)). Injection of anything into the 423 muscle can breach blood vessels and allow leak into the bloodstream. For an 424 intramuscular Ad vaccine, this can cause adenovirus to be absorbed by liver Kupffer cells, 425 liver sinusoidal endothelial cells, and to productively infect liver hepatocytes, spleen, or 426 lungs. It is therefore possible that injecting Ads into the muscle by this unnatural route 427 may elevate the risk of side effects. It is possible that delivering adenovirus vaccines by 428 intranasal vaccination may avoid some of these new risks. That having been said, it 429 should be noted that intranasal immunization has its own possible side effects including 430 retrograde transport into the olfactory bulb and Bell's palsy. 431 20 Another consideration is the use of adenoviruses that are low seroprevalent in humans. 432

The primary advantage of Ad26 and ChAdOx1 is that few people have been exposed 433 them naturally and so most people do not have neutralizing antibodies against these 434 vaccines. While that is true, it also means that there is less experience with how these 435 viruses behave in humans and what side effects may be observed. 436

In contrast, 27 to 100% of humans are immune to Ad5 (43). Ad6 is lower seroprevalent 437 than Ad5, with 4 to 22% of humans having already been exposed to Ad6 (48, 49). In both 438 cases, these humans have experienced these species C Ads after mucosal exposure 439 without obvious connections to side effects associated with COVID-19 vaccines. One 440 might say that both Ad5 and Ad6 have been field tested as mucosal vaccines in as many 441 as a billion humans. Conversely, no humans have been naturally exposed to Ad5, Ad6, 442 Ad26, or ChAdOx1 by intramuscular exposure. 443

While these common human adenoviruses may have some ironic safety value, it is still 444 possible that arming any adenovirus or any gene-based vaccine with the SARS-CoV-2 445 spike protein may by itself play a role in the observed thrombotic side effects by 446 intramuscular or mucosal routes of vaccination. 447

These concepts need to be explored further. Regardless, this study suggests that 448 mucosal immunization may have value when combating SARS-CoV-2 and other mucosal 449 pathogens. This work also suggests that giving adenovirus vaccines the ability to replicate 450 via single-cycle modifications may have value in increasing per virus potency or by 451 allowing more doses to be produced by using fewer virions per person. 452 

Safety and immunogenicity of the ChAdOx1 nCoV-19 603 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, 604 randomised controlled trial

Characterization of human adenovirus 606 serotypes 5, 6, 11, and 35 as anticancer agents

IIIa deleted adenovirus as a single-cycle genome 608 replicating vector

Use of the Syrian hamster as an animal 610 model for oncolytic adenovirus vectors

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to 613 convalescent sera and monoclonal antibodies

Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody 618

Resurgence of COVID-19 in Manaus, Brazil, despite 624 high seroprevalence

Protection against 626 divergent influenza H1N1 virus by a centralized influenza hemagglutinin

Low seroprevalent species D adenovirus vectors as 629 influenza vaccines

Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic 632 virotherapy against human prostate cancers

Comparison of the Life Cycles 634 of Genetically Distant Species C and Species D Human Adenoviruses Ad6

Ad26 in Human Cells

Characterization of species C human adenovirus serotype 6 (Ad6)

Comparative 642 seroprevalence and immunogenicity of six rare serotype recombinant adenovirus 643 vaccine vectors from subgroups B and D

Differential immunogenicity between HAdV-5 and chimpanzee 647 adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop 648 sequences in mice

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombotic Thrombocytopenia 653 after Ad26.COV2.S Vaccination

Current advances and future challenges in Adenoviral 655 vector biology and targeting

Vaccine vectors 660 derived from a large collection of simian adenoviruses induce potent cellular 661 immunity across multiple species

Incidence and 663 prevalence of neutralizing antibodies to the common adenoviruses in children with 664 cystic fibrosis: implication for gene therapy with adenovirus vectors

A) Schematics of replication-defective adenovirus (RD-Ad) spike vaccine 671 construct as compared to single-cycle adenovirus (SC-Ad) spike vaccine construct

RD-Ad spike vector, the E1 protein has been removed and the SARS-CoV-2 spike protein 673 has been inserted. In the SC-Ad spike vector, the pIIIA protein has been removed instead 674 of the E1 protein, and the SARS-CoV-2 spike protein has been inserted. B) Western blot 675 of human A549 lung cells infected with SC-Ad vector with GFP-Luciferase

RD-Ad spike, or SC-Ad spike at doses of 10 2 and 10 4 viral particles per cell

Cells were harvested 24 hours post-infection, and western blot was performed looking for 678 relative levels of SARS-CoV-2 spike protein

Male Syrian hamsters were 681 immunized at a dose of 10 9 vp, and serum was collected at weeks 2, 6, 14, 26 after single 682 immunization. Serum was used at 1:1000 dilution to test for SARS-CoV-2 spike IgG 683 antibodies by ELISA

Spike Antibody Production by RD-Ad and SC-Ad Vaccines after a Single 685

Intranasal or Intramuscular Vaccination. A) Male Syrian hamsters were immunized at 686 a dose of 10 9 vp, and serum was collected at 26 weeks (6 months) after single 687 immunization

CoV-2 spike IgG antibodies by ELISA. B) Male Syrian hamsters were immunized and 689 serum was collected at 6 weeks after single immunization. SARS-CoV-2 neutralization 690

Genscript) was performed at 1:10, 1:33, and 1:100 serum dilutions comparing RD-691

Ad spike and SC-Ad spike at intranasal and intramuscular routes of immunization. spike 692 inhibition rate was determined based on the formula

Comparison of serum spike IgG antibodies in Syrian hamsters immunized with RD-Ad 694

Ad spike by intramuscular (C) and intranasal (D) routes of administration, 695 analyzed by ELISA at 1:1000 serum dilution

Week 14 sera from SC-Ad 698 spike or SC-Ad-GL IM hamsters were analyzed for binding to variant RBDs and S1 699 proteins by ELISA at 1:1000, 1:10,000, and 1:20,000 dilutions. All levels of significance 700 are shown as compared to the sample's respective SC-Ad GL version

0001, ** = p<0.01, * = p<0.05). More detailed statistical comparisons are shown 702

Serum Antibody Production to Spike Protein after Single Intranasal or 704

Male BALB/c mice were 705 immunized at a dose of 10 10 vp virus, and serum was collected 2 weeks after single 706 immunization and was tested for SARS-CoV-2 spike

Mucosal Antibody Production to Spike Protein in Bronchoalveolar Lavages 709 (BALs) after Single Intranasal or Intramuscular Administration of SC-Ad-Spike in 710

Male BALB/c mice were immunized with 10 10 vp of SC-Ad-Spike and 711 bronchoalveolar lavage (BAL) fluid was collected at 8 weeks after single immunization

A) BAL fluid was used at 1:500 dilution to test for SARS-CoV-2 spike IgG and IgA 713 antibodies by ELISA. Plates were read at 450nm, and all analyses were done by one-714 way ANOVA. B) SARS-CoV-2 neutralization assay (Genscript) was performed at 1:10 715 dilution of BAL fluid, comparing IN SC-Ad Zika, IN SC-Ad spike and IM SC-Ad spike. spike 716 inhibition rate was determined based on the formula provided by Genscript

T Cell Populations in Bronchoalveolar Lavages (BALs) after

Single Intranasal or Intramuscular Administration of SC-Ad-Spike in Mice. 8 weeks 720 after single immunization of 10 10 vp of SC-Ad-Spike in BALB/c mice, BAL was performed

Cells were pelleted out of BAL fluid and analyzed by flow cytometry. A) Shows number 722

B) Shows number of CD4 T cells counted 723 that expressed IFN . C) Shows number of CD4 T cells